ERC1671 is in development for the treatment of high grade, recurrent gliomas. Gliomas are the most common type of primary brain tumour. They develop from the glial cells that support the nerve cells of the brain and spinal cord. Glioblastoma multiforme (GBM) is the most common and most malignant of all high grade gliomas. Gliosarcoma is a rare, malignant and fast-growing type of glioma, all classified as high grade tumours. High grade gliomas are very difficult tumours to treat due to the problems in completely removing the tumour and their resistance to radiotherapy and chemotherapy.
ERC1671 is composed of whole tumour cells and cell fragments taken from the patient and three other donors with the same type of cancer. By receiving tumour cells from different people, the patient’s immune system is exposed to several different tumour-associated antigens (TAA), or proteins, minimizing the chance that tumour cells might escape from the body’s defences. It also is believed this approach will trigger a stronger immune response against the TAA on the patient’s tumour. This strategy in combination with the immune response inherent in the patient’s own cells may lead to the elimination of glioblastoma cells and offer an additional treatment option for high grade glioma patients who currently have few effective therapies available.
Atezolizumab is currently in clinical development for the treatment of patients muscle-invasive urothelial cancer (MIUC) including muscle-invasive bladder cancer (MIBC) and upper tract urothelial cancer (UTUC) patients who are at high risk following resection. MIBC is a cancer that spreads into the thick muscle deep in the bladder wall. MIBC starts in the inner bladder layer and then grows in the deep muscle. While UTUC can arise along any part of the urinary tract lined with urothelium with the majority of cases in the lower tract and rest in the upper tract. Over time the tumour may grow outside the bladder into tissues close by and then may spread to lymph nodes, the lungs, the liver and other parts of the body. The current standard care of treatment includes a surgery which might not be adequate and some patients might be at high risk for recurrence.